CTRI/2022/12/047937进行中（未招募）2 期
A Dose Escalating, Randomized, Phase 2b Study to Assess the Safety, Tolerability and Efficacy of Ocular Drug-Delivering Contact Lens LL-BMT1 in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension. - NA
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects will be considered eligible for the study based on the following criteria:
- •1. Male or female subject of at least 18 years of age at the time of screening visit.
- •2. Diagnosed with POAG or OHT in both eyes.
- •3. At least one eye (called the study eye) must have an untreated IOP between 22 mmHg and 34 mmHg (both inclusive) as measured at 8 AM (± 1 hour) during the baseline visit. For eyes receiving IOP treatment, untreated IOP will be assessed following a required washout period as outlined below:
- •4 days washout for parasympathomimetic and topical or systemic carbonic anhydrase inhibitors.
- •2 weeks washout for sympathomimetics and alpha agonists
- •4 weeks washout for beta adrenergic blocking agents, combination product, Rho kinase inhibitors, and prostaglandin agonists.
- •4. If the fellow eye does not meet inclusion criterion #3 above, it must have an untreated IOP (following washout, if applicable) within 5 mmHg of the study eye IOP without exceeding the 34 mmHg maximum (e.g., a study eye IOP of 22 mmHg and a fellow eye IOP of 17 mmHg is allowed).
- •5. BCVA of Early Treatment Diabetic Retinopathy Study (ETDRS) of 50 letters or better or BCVA of 20/100 or better on Snellen’s chart in each eye.
- •6. Female of child-bearing potential must not be pregnant or lactating, must have a negative urine pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal (patch ?), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide.
- •7. No adverse reactions to nonmedicated contact lenses during the 2-week acclimation screening.
- •8. Score of 0-11 on CLDEQ-8 (Appendix-I), administered at the end of the 2-week acclimation screening
- •9. Willing and able to comply with the study procedure and sign a written informed consent
排除标准
- •Subjects will be excluded from the study based on the following criteria:
- •1. Glaucoma or optic neuropathy due to anything other than POAG or OHT
- •2. Cup-to-disc ratio of >0.8 (horizontal or vertical measurements) in either eye in screening or baseline visit
- •3. Corneal thickness <480 or >620 Micro m
- •4. IOP >34 mmHg in either eye at the screening visit or baseline Visit
- •5. Significant visual field loss, in the opinion of the investigator
- •6. Any severe and uncontrolled comorbid medical conditions which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject’s ability to participate in the study.
- •7. An active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening Visit
- •8. Current contact lens use for vision correction/ cosmetic purposes (unless willing to switch to glasses for the duration of the study)
- •9. Subject with current or a last 3-month history of severe dry eye in either eye
- •10. Subjects with meibomian gland dysfunction.
- •11. History of treated allergic, vernal, or atopic conjunctivitis
- •12. History of contact lens intolerance, corneal scarring, corneal neovascularization, giant papillary conjunctivitis, or any other corneal pathology that is deemed by the investigator to constitute a contraindication for applying contact lenses
- •13. Aphakia or presence of anterior chamber intraocular lens in either eye
- •14. History of clinically significant macular pathology (i.e., progressive age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, etc.) in either eye.
- •15. History of corneal refractive surgery (i.e., laser-assisted in situ keratomileusis [LASIK], photorefractive keratectomy [PRK], radial keratotomy [RK], small incision lenticule extraction [SMILE], or corneal inlay, etc.) in either eye.
- •16. History of prior incisional glaucoma surgery (i.e., bleb, shunt, seton, etc.) in either eye.
- •17. History within past 6 months of any ocular anterior segment laser or other intraocular surgery in either eye
- •18. Use of laser of any type on retina in either eye within 3 months prior to the screening visit.
- •19. History of punctal cautery or planned use of punctal plugs during the study in either eye.
- •20. Cataract surgery in either eye within 3 months, or other intraocular surgery in either eye within 6 months prior to the Screening Visit or planned during the course of the study.
- •21. Anticipated need for ocular surgery in either eye during the study period.
- •22. Required chronic use of topical or injectable ocular medications other than IOP-lowering medication, including artificial tears, or currently receiving chronic intravitreal injections.
- •23. Subjects with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure, overactive thyroid gland, myasthenia gravis.
- •24. Congestive heart failure (New York Heart Association [NYHA] class III & class IV), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, deep vein thrombosis (DVT), heart failure, Pulmonary Thromboembolism (PTE)
研究者
相似试验
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 17.0Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 17.0Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-GBShire ViroPharma Incorporated160
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 14.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-BEVIROPHARMA INCORPORATED160
进行中（未招募）
不适用
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patients.CMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 15.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 15.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-ESVIROPHARMA INCORPORATED160
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsEUCTR2010-024247-32-DEVIROPHARMA INCORPORATED159
进行中（未招募）
不适用
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 14.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-024247-32-FRVIROPHARMA INCORPORATED160